ArticleDiscover oncology2025
Unveiling the global research status and intellectual map of cancer and immunosuppressants.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe use of immune checkpoint inhibitors (ICIs) has significantly advanced cancer therapy, improving survival rates and prognosis for many patients. This study employs bibliometric methods to explore the current state and future trends in the field of immunosuppressants and cancer treatment.
methodsData were retrieved from the Science Citation Index Expanded for articles and reviews published between 2014 and 2024 in the Web of Science database. 2,352 records were analyzed using CiteSpace, VOSviewer, R software, and Microsoft Excel. The focus was on publication trends, citations, co-citation networks, keyword co-occurrence, and collaborative networks.
resultsThe study identified a steady increase in publications and citations, with an average annual growth rate of 3.93%. The United States and China were the leading countries in research output, while the University of Texas MD Anderson Cancer Center and Harvard Medical School were key institutions. Research hotspots included ICIs, tumor microenvironment, and immune-related adverse events. Interdisciplinary collaboration was highlighted as crucial for advancing the field.
conclusionsThe growing body of research on cancer and immunosuppressants highlights the need for optimizing immunotherapy protocols, managing drug resistance, and exploring the potential of immunosuppressants in cancer treatment. Strengthening international collaboration is vital for translating research findings into clinical practice and improving patient outcomes. Despite the comprehensive analysis, the study's reliance on the WoSCC database and English-language publications may limit the generalizability of findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.